CAMPs 2025 meeting highlights the use of CAMPs in all sites of care.

SmartTRAK reports the latest news and trends in cellular, acellular and matrix-like products (CAMPs) from the CAMPs 2025 Wound Care Summit held February 28 to March 2 in Fort Lauderdale, Florida. Hosted by the Journal of Wound Care (JWC), CAMPs 2025 showcased new clinical research, consensus guidelines and presentations supporting the use of CAMPs amid uncertainties in reimbursement for these products in the US Market for Skin Substitutes.

The subjects discussed in this downloadable SmartTRAK Perspective article include:

• The Broad Use of CAMPs
  • Sessions at CAMPs 2025 supported the broad use of CAMPs, including applications for diabetic foot ulcers (DFUs) and venous leg ulcers (VLUs) as well as those for limb salvage, acute care, tunneling wounds, Mohs surgery, trauma, burns and pressure ulcers (PrUs). SmartTRAK expects the use of CAMPs to ... (read more)
• LCD Discussions Taking Center Stage
  • With the implementation of the MAC LCDs delayed until April 13^th, a prevailing question among attendees at the conference was whether the LCDs would actually be implemented or further delayed. SmartTRAK spoke with clinicians and industry representatives to obtain their views on the LCDs and ... (read more)
• Market Disruption – 2025 Earnings Projections
  • For public companies providing skin substitutes to the market, uncertainty was a major theme in their 2025 guidance SmartTRAK  summarizes comments from companies that mentioned the LCD in their 2025 revenue projections ... (read more)

Although a significant amount of discussion with clinicians and industry focused on revising the reimbursement methodology for skin substitutes, companies are still moving forward with clinical studies. SmartTRAK is currently tracking 26 clinical trials for DFUs and VLUs, as mentioned earlier and ...

To find out more about news and trends from CAMPs 2025, just click the button below to download the complete market perspective article "LCD Uncertainty Bringing Disruption to CAMPs" by Susan Paquette, VP & General Manager, Wound.

---

SmartTRAK is the Medtech industry’s only global Insights-as-a-Service solution for the Orthopedics, Wound Care, Regenerative Medicine and Neuro Therapy markets. SmartTRAK’s propriety methodology turns disparate data from hundreds of sources into powerful insights customers can rely on as the trusted source for strategic decision-making. The SmartTRAK enterprise platform includes rich daily updates, comprehensive market coverage and simple-to-use tools and dashboards for market, product and financial analysis. Customers leveraging the SmartTRAK platform also have direct access to market experts for inquiries and advisory services. If you would like a demo of what SmartTRAK has to offer and see how we can help increase proficiency, improve productivity and reduce costs for your company, just click here.

SmartTRAK highlights four wound diagnostics companies utilizing artificial intelligence to watch in 2025.

Artificial intelligence (AI) is becoming increasingly ubiquitous in our personal and professional lives. AI is already being applied in healthcare in areas such as image analysis, personalized treatments and predictive care. Future potential applications include improved analysis of healthcare data, optimizing medication doses and enhancing patient education. The challenges of AI are also widely discussed, with ethical and legal concerns combined with a general worry that patient care could become dehumanized and distanced from healthcare professionals.

In this downloadable article, SmartTRAK identifies and discusses the following four diagnostic companies facilitating AI that should be watched in 2025:

• eKare
  • Wound assessment company eKare has been at the forefront of the conversation around AI in wound care. The core functionality of inSight, a 3D digital wound imaging system, includes AI aspects such as ... (read more)
• Mimosa Diagnostics
  • Canadian tissue oximetry company Mimosa Diagnostics primarily implements AI to enhance the usability of its Mimosa Pro device, which uses ... (read more)
• Spectral AI
  • Texas-based Spectral AI has undertaken significant fundraising over recent years. Over $150 million of Biomedical Advanced Research and Development Authority (BARDA) funding since 2013 has facilitated ... (read more)
• Swift Medical
  • Toronto-based Swift Medical saw a significant change in 2024. New leadership was announced in June as Dwayne Sansone and Stratos Davlos assumed the roles of CEO and CTO, respectively. The company received ... (read more)

The benefits of AI in wound care include accuracy and efficiency of wound characterization, remote monitoring, personalized care and increased accessibility to wound care ...

To find out more about how these companies are incorporating AI, just click the button below to download the complete market outlook article "Artificial Intelligence in Wound Diagnostics: Four Companies to Watch in 2025" by Kris Flinn, SmartTRAK General Manager, Wound.

SmartTRAK delves into recent spinal implant divestitures.

The global Spinal Implant Market has seen an increasing number of divestitures in recent years. Large strategics are streamlining their portfolios, while private equity firms and specialized manufacturers are capitalizing on the opportunity to acquire divested assets. In this article, SmartTRAK explores the key drivers behind these divestitures, notable transactions and the broader implications for the industry, including:

• Recent Divestitures from Key Players
  • In January, Stryker (SYK) announced a definitive agreement to sell its US spinal implants business to the Viscogliosi Brothers (VB), a New York-based investment firm focused on neuro and musculoskeletal technologies. VB Spine is set to become ... (read more)
• Why the Shake-ups? 
  • The Spine Hardware Market is characterized as a very SKU-heavy business with little differentiation among implants, making it expensive and requiring savvy and specialized operations to ensure profitability. Market-leading strategics, Medtronic (MDT) and Globus (GMED) are acquiring ... (read more)
• Focus on Interventional Market
  • With ZBH and SYK exiting the spinal fusion space altogether, other companies are targeting adjacent high-growth markets, where there is a much larger population of chronic low back pain (CLBP) patients to treat in lieu of fusion. Post divestiture, SYK will retain ... (read more)
• Continued Evolution Expected
  • Consolidation and specialization in the Spine Market could lead to improved product quality, better integration of new technologies and enhanced patient outcomes. SmartTRAK expects the Spine Market 
    will ...(read more)
    
    

Curious about the latest transactions and trends in the Spine Market and the broader implications for the industry? Click the button below to download the complete market outlook article, "Spine Market Shake-Up: Trends, Drivers and What’s Next" by Elise Wolf, SmartTRAK VP& GM, Orthopedics & Quality.

---

SmartTRAK is the Medtech industry’s only global Insights-as-a-Service solution for the Orthopedics, Wound Care, Regenerative Medicine and Neuro Therapy markets. SmartTRAK’s propriety methodology turns disparate data from hundreds of sources into powerful insights customers can rely on as the trusted source for strategic decision-making. The SmartTRAK enterprise platform includes rich daily updates, comprehensive market coverage and simple-to-use tools and dashboards for market, product and financial analysis. Customers leveraging the SmartTRAK platform also have direct access to market experts for inquiries and advisory services. If you would like a demo of what SmartTRAK has to offer and see how we can help increase proficiency, improve productivity and reduce costs for your company, just click here.

SmartTRAK spotlights Doron Therapeutics in an interview with CEO Alessandra Pavesio at CG 2025 Musculoskeletal Conference in San Diego. 

Alessandra Pavesio, CEO of Doron Therapeutics, discusses the company, recent milestones and MOTYS, the company’s placental-derived injectable therapeutic for osteoarthritis, in an interview with   SmartTRAK  at the Canaccord Genuity (CG) 2025 Musculoskeletal Conference in San Diego, March 10, 2025.

SmartTRAK highlights the key trends in the US Arthroscopic Technologies Market that will drive growth in 2025 and beyond.

The Arthroscopic Technologies (AT) Market is poised for significant advancements as we move through 2025 and beyond. With an anticipated compound annual growth rate (CAGR) of 4.3%, the US AT market is projected to rapidly expand by 2028. This growth is driven by technological innovations and the increasing prevalence of minimally invasive procedures.

In this downloadable market outlook article, SmartTRAK highlights the top technology trends to watch in 2025 that are shaping the future of AT, including:

• Continued Evolution in Arthroscopic Visualization
  • The arthroscopic visualization segment is undergoing a transformation driven by technological advancements and shifting market dynamics, increasing at ... (read more)
• Growth in Bundled Solutions
  • In the AT space, consumables such as resection tools, radiofrequency (RF) devices and fluid management products are significant revenue drivers. SmartTRAK estimates ... (read more)
• ASC Shift Driving Demand for All-in-One Solutions
  • The growth of ASCs has heightened the demand for all-in-one solutions, enabling sports medicine companies to ... (read more)
• Growing Interest in Direct Display Communications
  • SmartTRAK expects to see growing interest in direct display communications in 2025. Building on these advancements in integrated arthroscopic visualization, the next frontier is  ... (read more)
• Challenges and Future Outlook
  • While advancements in arthroscopic technologies are progressing, they remain ... (read more)

Want to stay ahead of the curve in arthroscopic technologies for 2025 and beyond? Click the button below to download Andy Knapik's market outlook article, "The Future of Arthroscopic Technologies in 2025 and Beyond." As SmartTRAK’s Sr Analyst, Soft Tissue Fixation and Arthroscopic Enabling Technologies, Andy provides an informative analysis of the latest market shifts, including the challenges ahead for the industry.

SmartTRAK highlights game-changing trends in orthobiologics for 2025 and beyond.

SmartTRAK highlights trends to watch in 2025 and beyond that will impact the US OrthoBiologics Market, which is projected to achieve a CAGR of 5.1% by 2028E. The OrthoBio Market has made significant strides over the past few years, primarily driven by breakthroughs in new technical approaches, product development and strong commercial execution.

In this downloadable article, SmartTRAK explores the current state of orthobiologic implants, focusing on two key segments, the Cartilage Replacement and Soft Tissue Replacement Markets, including:

• Emerging Biomaterials & Technologies – Products in Play for 2025 and Beyond
  
  • Cartilage Replacement
  • Soft Tissue Replacement
    
    • Soft Tissue Augmentation
    • Knee Ligament Replacement
• Clinical Trial Spotlights – Products on Deck for 2025 and Beyond
  
  • Cartilage
  • Soft Tissue Replacement
    
    • • Soft Tissue Augmentation
      • Knee Ligament Replacement

The article examines, in depth, companies that are in the line-up with clinical trials and the recent technological breakthroughs and regulatory milestones shaping the Orthobiologics market ...

Curious about the latest innovations and trends in the Orthobiologics Market for 2025?  Click the button below to download the complete market outlook article, "Game-Changing Innovations in Orthobiologics for 2025 and Beyond" by SmartTRAK's Emily Meng.

SmartTRAK highlights the key trends in the US Compression Therapy market that will drive growth over the next few years.

In the US Market for Compression Devices, SmartTRAK projects revenues to reach a 5-year CAGR of +6.2%. In 2025, SmartTRAK expects mid-single-digit growth to continue and sees three key trends that will help drive growth over the next several years. These include:

Dr. Marc Russo discusses his research on ultra-low frequency SCS and its potential to treat nociceptive back pain in an interview with SmartTRAK at NANS 2025. 

While spinal cord stimulation (SCS) has been a standard treatment for chronic neuropathic pain conditions for over 40 years, SCS technologies to date have not demonstrated efficacy in the treatment of chronic low back pain that is predominantly nociceptive in origin. At the recent North American Neuromodulation Society (NANS) 2025 Annual Meeting in Orlando, Dr. Marc Russo, a professor at the University of Newcastle in Australia, presented data evaluating the use of ultra-low frequency (ULF) SCS (Presidio Medical) for the treatment of nociceptive chronic low back pain, which affects a much larger segment of the population than those affected by chronic neuropathic pain.

While chronic low back pain can have a mix of both nociceptive and neuropathic pain, a technology that can effectively treat nociceptive pain, or even both types of pain, could be a game changer. In an interview with SmartTRAK, Dr. Russo discusses ULF SCS, its mechanism of action and how this research is charting new territory in the treatment of chronic low back pain.

To find out more about ULF SCS and Dr. Russo’s latest research, listen to the interview below (12:59 min). A link to download a complete transcript of the interview is also provided below. 

SmartTRAK: Anne Staylor here with SmartTRAK. Today, I'm at the North American Neuromodulation Society Annual Meeting and I have the opportunity to speak with Dr. Marc Russo, a professor at the University of Newcastle in Australia. 

Hi, Dr. Russo. So nice to see you again.

Dr. Marc Russo: Hi, Anne. Likewise.

I always like to talk to you about innovation. You seem to be on the leading edge of these things all the time. So here at the meeting, you've presented on a new technology that you've been studying, ultra-low frequency spinal cord stimulation. You presented a study. Let's start by having you provide an overview about what ultra-low frequency is for spinal cord stimulation and then we'll get into the study. Can you start with that?

Dr. Marc Russo: Yes. Absolutely. And I think we really have to set the scene by talking about the original research work that looked at how we could actually interact with nervous system tissue. So that work goes all the way back to the work of Huxley back in 1961. And in that, they showed  ... (read more)

Click the button below to download the full transcript of the interview "NANS 2025: Charting New Territory With Ultra-Low Frequency Spinal Cord Stimulation."  In this conversation, Dr. Mark Russo, past president of the International Neuromodulation Society and associate professor at the University of Newcastle, NSW, Australia, discusses his research on ultra-low frequency SCS and its potential to treat nociceptive back pain with Anne Staylor, SmartTRAK Executive Editor, VP & GM of Neuro Therapies.